跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/EUCTR2008-001551-22-IE
EUCTR2008-001551-22-IE进行中（未招募）不适用

A randomized, double-blind, placebo controlled, multicenter, phase II study of adding AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R) to first line chemotherapy in patients with optimally debulked ( < 1cm) epithelial ovarian cancer - TRIO 014

Cancer International Research Group0 个研究点目标入组 160 人开始时间: 2009年2月6日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
不适用
状态
进行中（未招募）
入组人数
160
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • •- Histologically-confirmed optimally debulked (< 1 cm) FIGO stage III or stage IV (positive pleural cytology only) ovarian epithelial (including fallopian tube and primary peritoneal) carcinoma.
  • •- Patients should have undergone surgical debulking, by a surgeon experienced in the management of ovarian cancer, with the aim of maximal surgical cytoreduction. All patients must be optimally debulked as defined as having no residual tumor of greater than 1 cm in the post surgical setting.
  • •- Patients with stage IV disease will be eligible if a positive pleural cytology is the only extra peritoneal disease.
  • •- Paraffin block (or 10 – 20 unstained slides) and fresh frozen surgical/biopsy specimens of the primary tumor are required at baseline.
  • •- No prior systemic treatment in the primary disease treatment setting.
  • •- Female > 18 years of age or legal age.
  • •- ECOG performance status = 2.
  • •- Adequate organ and bone marrow function as evidenced by:
  • •- hemoglobin = 9.0 g/dL,
  • •- absolute neutrophil count = 1.5 x 109/L,
  • •- platelet count = 100 x 109/L,
  • •- Serum creatinine = 1.5 x ULN and measured or calculated creatinine clearance = 60 mL/min.
  • •- AST and ALT = 2.5 x ULN
  • •- total bilirubin = 1.5 x ULN unless increase is due to Gilbert’s disease or similar syndrome involving slow conjugation of bilirubin,
  • •- Non diabetic patients or Type 1 or 2 Diabetic Patients:
  • •- Diabetes must be controlled with HgbA1c < 8% and fasting blood glucose level <160 mg/dL.
  • •- Patient must be willing and able to comply with scheduled visits, and all study procedures.
  • •- Informed consent obtained.
  • •- Patients should be able to commence systemic therapy within 6 weeks of cytoreductive surgery.
  • •- Life expectancy > 12 weeks.
  • •- Adequate coagulation parameters (within 14 days prior to randomization), International Normalized Ratio (INR) =1.5; Activated Prothrombin Time (APTT) = 1.5 x ULN.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 160
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 160

排除标准

  • •- Non-epithelial ovarian cancer, including malignant mixed Mullerian tumors.
  • •- Borderline tumors (tumors of low malignant potential).
  • •- Planned intraperitoneal cytotoxic chemotherapy.
  • •- Prior systemic anticancer therapy for ovarian cancer.
  • •- Any previous radiotherapy to the abdomen or pelvis.
  • •- Patients with synchronous primary endometrial carcinoma, or a past history of primary endometrial carcinoma, are excluded unless ALL of the following criteria for describing the endometrial carcinoma are met: Stage = Ib, no more than superficial myometrial invasion, no lymphovascular invasion, not poorly differentiated (i.e., not Grade 3 or papillary serous or clear cell).
  • •- Diagnosis of any second malignancy within the last 5 years, except for adequately treated basal cell or squamous cell skin cancer, or in situ carcinoma of the cervix uteri.
  • •- Prior treatment with a humanized monoclonal antibody anticancer therapeutic.
  • •- Prior treatment with investigational treatment targeted to IGF axis including, but not limited to, CP 751,871, IM-A12, RO4858696.
  • •- Previous exposure to AMG 479.
  • •- Anticipation of a need for a major surgical procedure or radiation therapy during the study.
  • •- History of hypersensitivity to recombinant proteins.
  • •- Treatment with radiotherapy, surgery, or an investigational agent within 4 weeks of randomization.
  • •- Any of the following within 6 months prior to study enrollment: myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, NYHA class III or IV congestive heart failure, cerebrovascular accident or transient ischemic attack, grade = 2 peripheral neuropathy, pulmonary embolism, deep vein thrombosis, or other thromboembolic event.
  • •- History of brain metastases, spinal cord compression, or carcinomatous meningitis.
  • •- Patient of child-bearing potential is pregnant (eg, positive human chorionic gonadotropin test) or is breast feeding.
  • •- Patient of child-bearing potential is not willing to use adequate contraceptive precautions.
  • •- Known active infection, or on antiretroviral therapy for HIV disease.
  • •- Known positive test for chronic hepatitis B or C infection.
  • •- Any other underlying physical or mental condition rendering the patient unable to understand the nature, scope, and possible consequences of the study.
  • •- Refusal or inability to give informed consent to participate in the study.
  • •- Other severe acute or chronic medical or psychiatric condition, or significant laboratory abnormality requiring further investigation that may cause undue risk for the patient’s safety, inhibit protocol participation, or interfere with interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study

研究者

相似试验

进行中（未招募）
不适用
A randomized, double-blind, placebo controlled, multicentre study to determine the effect of QVA149 on lung function in patients with Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 9.1Level: LLTClassification code 10009033Term: Chronic obstructive pulmonary diseaseChronic Obstructive Pulmonary Disease
EUCTR2007-003655-36-BEovartis Pharma140
进行中（未招募）
不适用
A randomized, double-blind, placebo controlled, multicenter regimen finding study of subcutaneously administered AIN457, assessing Psoriasis Area and Severity Index (PASI) response in patients with moderate to severe chronic plaque-type psoriasis. - A2211Moderate to severe plaque-type psoriasisMedDRA version: 9.1Level: LLTClassification code 10050576Term: Psoriasis vulgaris
EUCTR2008-007525-39-ISovartis Pharma Services AG459
进行中（未招募）
1 期
A randomized, double-blind, placebo controlled, multicenter, phase II study of adding AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R) to first line chemotherapy in patients with optimally debulked ( < 1cm) epithelial ovarian cancer
EUCTR2008-001551-22-FRCancer International Research Group170
进行中（未招募）
不适用
A randomized, double-blind, placebo controlled, multicenter regimen finding study of subcutaneously administered AIN457, assessing Psoriasis Area and Severity Index (PASI) response in patients with moderate to severe chronic plaque-type psoriasis.Moderate to severe plaque-type psoriasisMedDRA version: 9.1Level: LLTClassification code 10050576Term: Psoriasis vulgaris
EUCTR2008-007525-39-FRovartis Pharma Services AG459
进行中（未招募）
不适用
A randomized, double-blind, placebo controlled, multicenter Phase II study to assess the efficacy and safety of Sorafenib added to standard treatment with Topotecan in patients with platinum-resistant recurrent ovarian cancer - TRIAS 2009This study is a prospective, randomized, double-blind, multi-center placebo-controlled phase II study in order to determine progression-free survival of patients with platinum-resistant or refractory ovarian carcinoma treated with topotecan plus sorafenib versus topotecan plus placebo.
EUCTR2009-011922-33-DECharité - Universitätsmedizin Berlin184